Fulcrum Therapeutics Inc FULC.OQ FULC.O is expected to show no change in quarterly revenue when it reports results on May 1 for the period ending March 31 2025
LSEG's mean analyst estimate for Fulcrum Therapeutics Inc is for a loss of 29 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Fulcrum Therapeutics Inc is $4.00, above its last closing price of $3.57.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.29 | -0.32 | -0.31 | Beat | 3.6 |
Sep. 30 2024 | -0.41 | -0.41 | -0.35 | Beat | 13.7 |
Jun. 30 2024 | 0.02 | -0.01 | 0.87 | Beat | 7,060 |
Mar. 31 2024 | -0.44 | -0.44 | -0.43 | Beat | 1.7 |
Dec. 31 2023 | -0.42 | -0.43 | -0.40 | Beat | 6 |
Sep. 30 2023 | -0.43 | -0.43 | -0.39 | Beat | 10.3 |
Jun. 30 2023 | -0.45 | -0.44 | -0.38 | Beat | 14.5 |
Mar. 31 2023 | -0.47 | -0.46 | -0.41 | Beat | 10 |
This summary was machine generated April 29 at 13:12 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)